Monitor for the future filing of the commercialization agreement which will contain financial terms, revenue sharing, and royalty structures. The partnership represents a strategic expansion into AI-driven pharmaceutical automation but carries execution risk as commercial terms are still to be negotiated.
Price Chart
Executive Summary
Oncotelic Therapeutics entered into a joint development, manufacturing, and licensing agreement with TechForce Robotics to create an AI-enabled, GMP-compliant robotic system for pharmaceutical manufacturing. The partnership combines Oncotelic's PDAOAI platform with TechForce's robotics hardware, with Oncotelic retaining exclusive ownership of all AI-related intellectual property and data generated by the product.
Key Financial Metrics
Key Facts
- Oncotelic and TechForce Robotics entered into a joint development agreement for an AI-enabled, GMP-compliant robotic system
- The product combines Oncotelic's PDAOAI AI platform with TechForce's robotic hardware
- Oncotelic retains exclusive ownership of all AI-related intellectual property and data generated by the product
- TechForce retains exclusive ownership of robotic hardware developments
- Jointly developed IP will be co-owned
- A separate commercialization agreement with financial terms will be negotiated before any revenue-generating activities
- Either party can terminate the agreement with 60 days notice
Financial Impact
No financial terms disclosed in the filing
Risk Factors
- Commercial success depends on future negotiations of revenue sharing and licensing terms
- Execution risk in developing and commercializing the integrated AI-robotics platform
- Dependence on partnership with TechForce Robotics for hardware components
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-014831 |
| Exhibit: ex99-1.htm | 0001493152-26-014831 |
| Document: form8-k.htm | 0001493152-26-014831 |
| Document: 0001493152-26-014831-index-headers.html | 0001493152-26-014831 |
| Document: 0001493152-26-014831-index.html | 0001493152-26-014831 |
| Document: 0001493152-26-014831.txt | 0001493152-26-014831 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $0.0200 | awaiting T+60 | — | $0.0200 (−0.00%) |
Oct 13, 2026 13d ago | 8-K | $0.0200 | awaiting T+60 | — | $0.0200 (−0.00%) |
Jul 14, 2026 14w ago | 8-K | $0.0400 $0.0200 | ▼ −50.00% | ▼ −52.79% | $0.0200 (−50.00%) |
Jun 29, 2026 17w ago | 8-K | $0.0400 $0.0245 | ▲ +38.75% | ▲ +42.59% | $0.0200 (+50.00%) |
May 5, 2026 24w ago | 8-K | $0.0400 $0.0400 | · 0.00% | ▼ −2.06% | $0.0200 (−50.00%) |
Apr 16, 2026 27w ago | 8-K | $0.0400 $0.0360 | ▼ −10.00% | ▼ −17.05% | $0.0200 (−50.00%) |
Apr 2, 2026 29w ago | 8-K | $0.0400 $0.0400 | · 0.00% | ▼ −14.16% | $0.0200 (−50.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers